Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0E0ZS
|
|||
Former ID |
DNC011105
|
|||
Drug Name |
N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide
|
|||
Synonyms |
CHEMBL1215730; BDBM50324614
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C20H18N2O
|
|||
Canonical SMILES |
CC(=O)NC1=CC=CC(=C1)C2=CC=C(C=C2)CC3=CC=NC=C3
|
|||
InChI |
1S/C20H18N2O/c1-15(23)22-20-4-2-3-19(14-20)18-7-5-16(6-8-18)13-17-9-11-21-12-10-17/h2-12,14H,13H2,1H3,(H,22,23)
|
|||
InChIKey |
HURKLDLRCGKBKL-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Steroid 11-beta-hydroxylase (CYP11B1) | Target Info | Inhibitor | [1] |
Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [1] | |
BioCyc | Superpathway of steroid hormone biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Androgen biosynthesis | ||||
Mineralocorticoid biosynthesis | ||||
KEGG Pathway | Steroid hormone biosynthesis | |||
Metabolic pathways | ||||
Ovarian steroidogenesis | ||||
Prolactin signaling pathway | ||||
Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
Steroidogenesis | ||||
Reactome | Androgen biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Endogenous sterols | ||||
WikiPathways | Metapathway biotransformation | |||
Steroid Biosynthesis | ||||
Oxidation by Cytochrome P450 | ||||
Metabolism of steroid hormones and vitamin D | ||||
Glucocorticoid & Mineralcorticoid Metabolism | ||||
Prostate Cancer | ||||
Phase 1 - Functionalization of compounds | ||||
Corticotropin-releasing hormone |
References | Top | |||
---|---|---|---|---|
REF 1 | Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.